{"id":607456,"date":"2022-07-11T11:30:02","date_gmt":"2022-07-11T11:30:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=607456"},"modified":"2022-07-11T11:30:02","modified_gmt":"2022-07-11T11:30:02","slug":"sarcopenia-market-size-analysis-growth-opportunities-pipeline-development-activities-emerging-therapies-and-epidemiology-forecast-key-companies-sanofi-lipocine-inc","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/sarcopenia-market-size-analysis-growth-opportunities-pipeline-development-activities-emerging-therapies-and-epidemiology-forecast-key-companies-sanofi-lipocine-inc_607456.html","title":{"rendered":"Sarcopenia Market Size Analysis, Growth Opportunities, Pipeline Development Activities, Emerging Therapies, and Epidemiology Forecast | Key Companies &#8211; Sanofi, Lipocine Inc."},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1657539375.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Sarcopenia Market Size Analysis, Growth Opportunities, Pipeline Development Activities, Emerging Therapies, and Epidemiology Forecast | Key Companies - Sanofi, Lipocine Inc.\" src=\"https:\/\/www.abnewswire.com\/uploads\/1657539375.jpeg\" alt=\"Sarcopenia Market Size Analysis, Growth Opportunities, Pipeline Development Activities, Emerging Therapies, and Epidemiology Forecast | Key Companies - Sanofi, Lipocine Inc.\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">DelveInsight\u2019s \u201cSarcopenia Market Insights, Epidemiology, and Market Forecast-2032\u2033 report offers an in-depth understanding of Sarcopenia, historical and forecasted epidemiology as well as the Sarcopenia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/div>\n<p style=\"text-align: justify;\">DelveInsight has launched a new report on &#8220;Sarcopenia Market Insights, Epidemiology, and Market Forecast-2032&rdquo;.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s &ldquo;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/sarcopenia-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Sarcopenia Market<\/a> Insights, Epidemiology, and Market Forecast-2032&Prime; report offers an in-depth understanding of Sarcopenia, historical and forecasted epidemiology as well as the Sarcopenia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Some of the key facts of the Sarcopenia Market Report:&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li>The market size of Sarcopenia was estimated to be USD 1,252 Million in 2021 and is anticipated to increase during the study period&nbsp;<\/li>\n<li>In the 7MM the total prevalence of Sarcopenia was estimated to be 35,794,548 cases in the year 2021&nbsp;<\/li>\n<li>Among the other countries in the 7MM, the highest prevalence of Sarcopenia was estimated to be in the United States accounting for almost 53% of the total prevalent cases&nbsp;<\/li>\n<li>The Gender-based epidemiology of Sarcopenia states that males are affected more as compared to females from the disease&nbsp;<\/li>\n<li>Amongst the EU-5 countries, Italy had the highest number of cases followed by Germany with 3,556,282 and 3,194,532 cases respectively. Spain accounted for the least number of sarcopenia cases in 2021<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Request a sample for the Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/sarcopenia-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">https:\/\/www.delveinsight.com\/sample-request\/sarcopenia-market<\/a><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Key benefits of the report:<\/p>\n<ol style=\"text-align: justify;\" start=\"1\">\n<li>Sarcopenia market report covers a descriptive overview and comprehensive insight of the Sarcopenia Epidemiology and Sarcopenia market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) &amp; Japan.)<\/li>\n<li>The Sarcopenia market report provides insights on the current and emerging therapies.<\/li>\n<li>Sarcopenia market report provides a global historical and forecasted market covering drug outreach in 7MM.<\/li>\n<li>The Sarcopenia market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Sarcopenia market.&nbsp;<\/li>\n<\/ol>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Got queries? Click here to know more about the <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/sarcopenia-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Sarcopenia Market Landscape<\/a>&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Sarcopenia Overview:&nbsp;<\/p>\n<p style=\"text-align: justify;\">Sarcopenia is a condition that is characterized by loss of muscle mass, muscle strength, and functional muscle impairment with aging. The definition has been through various alterations. However, an enormous recent breakthrough is the inclusion of the condition in the ICD-10 classification of diseases. The physical consequences of this disease put a person at risk for falls, fractures, and hospitalization, thereby affecting the quality of life and death in extreme cases.&nbsp;<\/p>\n<p style=\"text-align: justify;\">The etiology of Sarcopenia is a constellation of factors involving the aging neuromuscular machinery (motor unit number and efficiency, muscle architecture and orientation, fiber type distribution), reduced anabolic hormone levels, and muscle disuse, and inflammation, driven by environmental, genetic and behavioral factors. &bull; In 2016, an ICD-10-CM (International Statistical Classification of Diseases and Related Health Problems, revision.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Sarcopenia Symptoms:&nbsp;<\/p>\n<p style=\"text-align: justify;\">The symptoms of Sarcopenia include &ndash;&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li>Falling due to unconsciousness<\/li>\n<li>Muscle weakness<\/li>\n<li>Slow walking speed<\/li>\n<li>Difficulty in maintaining a normal routine&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Sarcopenia Market &nbsp;<\/p>\n<p style=\"text-align: justify;\">The dynamics of the Sarcopenia market are anticipated to change in the coming years owing to the expected launch of emerging therapies such as REGN1033, Bimagrumab, and others during the forecasted period 2019-2032.&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Learn more by requesting for sample @<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/sarcopenia-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Sarcopenia Market Landscape<\/a>&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Sarcopenia Pipeline Therapies:<\/p>\n<ul style=\"text-align: justify;\">\n<li>REGN1033<\/li>\n<li>Bimagrumab<\/li>\n<li>LPCN 1148<\/li>\n<li>BIO101&nbsp;<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Sarcopenia Pipeline Key Companies:&nbsp;<\/p>\n<ul style=\"text-align: justify;\">\n<li>Sanofi<\/li>\n<li>Lipocine Inc.<\/li>\n<li>Novartis Pharmaceuticals<\/li>\n<li>Regeneron Pharmaceuticals<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Table of Contents&nbsp;<\/p>\n<p style=\"text-align: justify;\">1. Sarcopenia Market Report Introduction<\/p>\n<p style=\"text-align: justify;\">2. Executive Summary<\/p>\n<p style=\"text-align: justify;\">3. SWOT analysis<\/p>\n<p style=\"text-align: justify;\">4. Sarcopenia Patient Share (%) Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">5. Sarcopenia Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">6. Sarcopenia Disease Background and Overview<\/p>\n<p style=\"text-align: justify;\">7. Sarcopenia Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">8. Country-Specific Patient Population of Sarcopenia&nbsp;<\/p>\n<p style=\"text-align: justify;\">9. Sarcopenia Current Treatment and Medical Practices<\/p>\n<p style=\"text-align: justify;\">10. Sarcopenia Unmet Needs<\/p>\n<p style=\"text-align: justify;\">11. Sarcopenia Emerging Therapies<\/p>\n<p style=\"text-align: justify;\">12. Sarcopenia Market Outlook<\/p>\n<p style=\"text-align: justify;\">13. Country-Wise Sarcopenia Market Analysis (2018&ndash;2030)<\/p>\n<p style=\"text-align: justify;\">14. Market Access and Reimbursement of Therapies<\/p>\n<p style=\"text-align: justify;\">15. Market drivers<\/p>\n<p style=\"text-align: justify;\">16. Market barriers<\/p>\n<p style=\"text-align: justify;\">17. Appendix<\/p>\n<p style=\"text-align: justify;\">18. Sarcopenia Report Methodology<\/p>\n<p style=\"text-align: justify;\">19. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">20. Disclaimer<\/p>\n<p style=\"text-align: justify;\">21. About DelveInsight&nbsp;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">Click here to read more about <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/sarcopenia-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=gpr\">Sarcopenia Market Outlook 2032<\/a><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_57048.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Gaurav Bora<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=sarcopenia-market-size-analysis-growth-opportunities-pipeline-development-activities-emerging-therapies-and-epidemiology-forecast-key-companies-sanofi-lipocine-inc\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> +91 9568243403<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=sarcopenia-market-size-analysis-growth-opportunities-pipeline-development-activities-emerging-therapies-and-epidemiology-forecast-key-companies-sanofi-lipocine-inc\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>DelveInsight\u2019s \u201cSarcopenia Market Insights, Epidemiology, and Market Forecast-2032\u2033 report offers an in-depth understanding of Sarcopenia, historical and forecasted epidemiology as well as the Sarcopenia market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/sarcopenia-market-size-analysis-growth-opportunities-pipeline-development-activities-emerging-therapies-and-epidemiology-forecast-key-companies-sanofi-lipocine-inc_607456.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[447,405,417,406,423],"tags":[],"class_list":["post-607456","post","type-post","status-publish","format-standard","hentry","category-Education","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/607456","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=607456"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/607456\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=607456"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=607456"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=607456"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}